FGFR2 and gastric cancer: The information from these analyses has indicated several actionable genetic alterations such as HER2 amplification (~ 15%, more commonly seen in GEJ and CIN), mesenchymal–epithelial transition (MET) amplification (~ 20%), fibroblast growth factor receptor 2 (FGFR2) amplification/mutation (~ 5–10%), PD-L1 amplification (more commonly seen in EBV infection), MSI-high (~ 15%), etc. These findings provide opportunities for personalized treatment in advanced GC.